June 1, 2015 — A Bad Day for Big-Pharma PR
On Monday, June I, 2015 the Wall Street Journal ran two items decrying big pharma’s manufacturing and pricing practices that are denying many cancer patients of their needed medicines. Manufacturing and pricing are two very basic functions of any production business and should have been mastered in the companies’ infancies.
However, both France’s Sanofi SA and U.S.-based Merck & Co., the only two manufacturers of BCG, a lifesaving cancer treatment, have been unable to keep the product in adequate supply for more than two years.
It is irresponsible for the only two producers of a potentially life-saving drug cannot manage their manufacturing processes in a manner to keep adequate supplies available.
Click here to read a complete summary.